Later, EGFR was associated with the development of specific EGFR tyrosine kinase inhibitors (EGFR-TKIs), producing substantial responses and improving clinical outcomes in NSCLC patients whose tumors harbor activating mutations in the EGFR gene (namely, exon 19 deletions and exon 21 L858R point mutation) [4,5,6]. Here, EGFR is linked to non-small cell lung carcinoma.